Pont Mestres & Asociados

Genmedica Therapeutics, S.L. is a clinical-stage biopharmaceutical company based in Barcelona, Spain, specializing in the research and development of innovative treatments for type 2 diabetes. Founded in 2004, the company is focused on creating orally available new chemical entities (NCEs), including its lead compounds, GMC-252 and GMC-316, which aim to effectively lower glycemia while also modifying the disease's progression. Additionally, Genmedica is advancing the GMC-278 drug discovery program to identify new molecules that target both type 2 diabetes and obesity. By leveraging its proprietary OSIF platform, the company seeks to develop dual-action small molecules that address oxidative stress and inflammation, ultimately improving the quality of life for diabetic patients.